tickerade

@tickerade.bsky.social

2 months ago

#MYNZ presenting new pancreatic cancer detection data at AACR conference, expanding early cancer detection capabilities

tickerade

@tickerade.bsky.social

2 months ago

#MYNZ: swing trader's opportunity with violent wicks between $1.10 and $1.30, repeating news-driven spikes.

tickerade

@tickerade.bsky.social

2 months ago

🧬🤖 Mainz Biomed #MYNZ is developing early-detection blood tests using amino acid biomarkers + AI, promising science, but still waiting on clear revenue drivers.

tickerade

@tickerade.bsky.social

2 months ago

#MYNZ repeating news-driven spikes between $1.10 and $1.30, offering opportunities for traders

StockTitan

@stocktitan.net

3 months ago

Mainz Biomed Provides Review of 2025 Highlights Initiation of eAArly DETECT 2 - U.S. Clinical Study to Evaluate Performance of Next Generation Test on Advanced Adenomas over Large Patient Population in Preparation for ReconAAsense U.S. FDA Pivotal Trial Results from Feasibility Study of Biomarker Panel in Pancreatic Cancer Project Study

#MYNZ Mainz Biomed Provides Review of 2025 Highlights

www.stocktitan.net/news/MYNZ/mainz-biomed-p...

tickerade

@tickerade.bsky.social

3 months ago

#MYNZ small diagnostics player gains traction in Europe, partners with big names & eyes US market growth

StockTitan

@stocktitan.net

4 months ago

Mainz Biomed and OncoVanguard8 Enter into Agreement to bring ColoAlert to South America Mainz Biomed (NASDAQ:MYNZ) signed a Memorandum of Understanding with OncoVanguard8 to introduce ColoAlert, a DNA-based colorectal cancer screening test, to South America beginning with Peru. The MOU outlines core commercial, legal and regulatory terms and a go-to-market strategy for an initial territory, with a final distribution agreement targeted within weeks.The companies identified Peru, Colombia and Ecuador as initial launch markets, where about 17,000 new colorectal cancer cases are diagnosed annually, highlighting demand for early-detection screening solutions that could raise participation and support public health goals.

#MYNZ Mainz Biomed and OncoVanguard8 Enter into Agreement to bring ColoAlert to South America

www.stocktitan.net/news/MYNZ/mainz-biomed-a...

StockTitan

@stocktitan.net

4 months ago

Mainz Biomed Showcases Innovative Cancer Detection Solutions at MEDICA 2025 Mainz Biomed (NASDAQ:MYNZ) will participate in MEDICA 2025 in Düsseldorf from November 17–20, 2025. MEDICA expects >5,000 exhibitors from 70 countries and about 80,000 visitors, offering a global platform for medical-technology networking, forums, and business development.Mainz Biomed will showcase its flagship molecular stool-based colorectal cancer screening test ColoAlert and preview additional early-stage cancer diagnostic solutions. The company will be at the Rhineland-Pfalz joint booth in Hall 3, E92. Investors and attendees are directed to the company investor site for more information and social channels for updates.

#MYNZ Mainz Biomed Showcases Innovative Cancer Detection Solutions at MEDICA 2025

www.stocktitan.net/news/MYNZ/mainz-biomed-s...

blaqsbi.com

@blaqsbi.com

4 months ago

News/Opinion: A woman who caused a fatal crash involving Khyree Jackson, an NFL rookie, has entered a plea in an updated situation. The Tragedy of Cori Clingmans Crucial Cry After Khyree Jacksons Fatal CrashIn the wake of Khyree Jackson’s fatal car crash over a year ago, Cori Clingman, who claimed to have been the crash driver, entered her criminal plea in response to the tragedy. This was a moment of profound significance for both the man and his family, as well as for the NFL community. The incident has highlighted the fragility of human lives and the complexities of legal proceedings in such tragic situations.### Khyree Jackson: The Man of HeartsKhyree Jackson, the former NFL rookie and kickboxer, was a rising star in the sport who made history with his stunning performance as the 2017 NFL Player of the Year. In early December, he was involved in a fatal car crash that claimed his life on a highway near Philadelphia. This accident marked a turning point for Khyree’s family and his community, as he faced not only financial compensation but also legal challenges.### The crash: A tragedyThe exact circumstances of Khyree’s death were widely reported, with details suggesting that he was driving in the center of the road when the collision occurred. Two cars, one northbound and one southbound, collided head-on, resulting in multiple fatalities and serious injuries. The crash was attributed to his negligent driving, which contributed to the tragedy.### Cori Clingman: The crash driverCori Clingman, a 25-year-old woman who had not yet publicly admitted her involvement with the crash, claimed to have driven the vehicle that suffered the fatal accident. In a letter written in December of this year, she described the incident as a “tremendous day” for all involved. She emphasized that she knew nothing about what happened and expressed no personal feelings regarding the situation.### Enter your plea: The legal dramaIn response to Khyree’s death, Cori Clingman entered her criminal plea in court on January 4, 2023. In response to this move, her attorney filed a motion for judgment on the merits of the case against her. While the details are still being finalized, it is clear that she has taken drastic steps toward a resolution and has made significant efforts to recover from the crash.### The legal implicationsThe situation involving Cori Clingman’s criminal plea reflects broader trends in legal proceedings related to violent crimes, particularly those involving individuals who have already committed deaths. Such cases often require more than just financial compensation; they also demand accountability and legal action to ensure that justice be served.### The community’s reactionAs the tragedy unfolded, the NFL community, Khyree Jackson’s family, and Cori Clingman’s attorney expressed their deepest condolences. Public sentiment mirrored the legal process: many recalled the tragedy and expressed grief for both Khyree and Cori. However, there has also been a growing awareness of the complexities of legal proceedings in such cases.### The aftermathThe situation involving Cori Clingman’s criminal plea is just one of many that have unfolded in response to tragic events like this. It serves as a reminder of the human cost of violence and the importance of seeking justice for all involved. As the NFL continues to grapple with the aftermath of Khyree Jackson’s death, Cori Clingman’s actions are seen not only as a part of her own legal battle but also as a step toward healing and closure.In summary, Cori Clingman’s entry into her criminal plea following Khyree Jackson’s fatal crash is a significant moment in the fight for justice. It highlights the fragility of human lives, the complexities of legal proceedings, and the importance of transparency and accountability in such cases. As the NFL community looks to address this tragedy, we can hope that the public remains compassionate and that the law ultimately leads to a more just outcome for all involved.------#News #CoriClingman #CoriClingmandriverKhyreeJackson #CoriClingmandriverpleadsguilty #CoriClingmandriverwhokilledKhyreeJackson #CoriClingmandriverwhokilledKhyreeJacksonguiltyplea #featured #KhyreeJackson #KhyreeJacksonaccidentupdates #KhyreeJacksoncaraccident #KhyreeJacksoncarwreck #KhyreeJacksondied #KhyreeJacksonNFLplayer #KhyreeJacksonNFLrookie #KhyreeJacksonpassesaway #KhyreeJacksonrookiedeath #NFLrookiediescaraccident

News/Opinion: A woman who caused a fatal crash involving Khyree Jackson, an NFL rookie, has entered a plea in an updated situation.: The Tragedy of Cori Clingmans Crucial Cry After Khyree Jacksons Fatal CrashIn the wake of Khyree Jackson’s… #MYNZ #News #CoriClingman #CoriClingmandriverKhyreeJackson

StockTitan

@stocktitan.net

5 months ago

Mainz Biomed Reports Topline Results from Feasibility Study of Biomarker Panel in Pancreatic Cancer Project Mainz Biomed (NASDAQ:MYNZ) reported topline feasibility results for a non-invasive, blood-based pancreatic cancer screening test using 18 licensed biomarkers. In a 30-subject cohort the leading panel achieved 100% sensitivity and 95% specificity, and the algorithm also detected precancerous lesions. These results align with earlier discovery/validation datasets that showed 95% sensitivity and 98% specificity. Mainz Biomed will plan a larger confirmatory study using banked retrospective samples, then a PCR-based validation study and potential future FDA submission, pending outcomes.

#MYNZ Mainz Biomed Reports Topline Results from Feasibility Study of Biomarker Panel in Pancreatic Cancer Project

www.stocktitan.net/news/MYNZ/mainz-biomed-r...

StockTitan

@stocktitan.net

6 months ago

Major Cancer Detection Breakthrough: Mainz Biomed's ColoAlert Test Launches in Swiss Market via Key Lab Partnership Mainz Biomed partners with labor team w ag to launch ColoAlert colorectal cancer screening test in Switzerland following Swissmedic approval. 2,000-patient study continues toward end-2025 completion.

#MYNZ Mainz Biomed Announces Commercial Launch of ColoAlert® in Switzerland

www.stocktitan.net/news/MYNZ/mainz-biomed-a...

StockTitan

@stocktitan.net

7 months ago

44,000 Annual Cancer Cases: Mainz Biomed's ColoAlert Test Gets UK Approval for Colorectal Screening DNA-based colorectal cancer screening test ColoAlert receives MHRA registration in UK market of 4M eligible patients. Partners with EDX Medical for nationwide laboratory services.

#MYNZ Mainz Biomed Announces Registration of ColoAlert in the United Kingdom

www.stocktitan.net/news/MYNZ/mainz-biomed-a...

StockTitan

@stocktitan.net

7 months ago

New Non-Invasive Colon Cancer Test Gets Swiss Green Light, Targets 2.8M Potential Users Swiss regulator approves ColoAlert's non-invasive colorectal cancer screening test, opening access to 2.8M potential users amid low screening rates. Learn market impact.

#MYNZ Mainz Biomed Receives Swiss Regulatory Approval to Market ColoAlert®

www.stocktitan.net/news/MYNZ/mainz-biomed-r...

StockTitan

@stocktitan.net

8 months ago

Mainz Biomed Announces Pricing of $3.0 Million Follow-On Offering of Ordinary Shares and Warrants Mainz Biomed (NASDAQ:MYNZ), a molecular genetics diagnostic company focused on early cancer detection, has announced the pricing of a $3.0 million follow-on offering. The offering consists of 2,222,222 units priced at $1.35 per unit, with each unit including one ordinary share (or pre-funded warrant) and one Series A warrant.The Series A warrants will be immediately exercisable at $1.35 per share with a five-year expiration term. Maxim Group LLC serves as the sole placement agent, with the offering expected to close around August 5, 2025, subject to customary conditions.

#MYNZ Mainz Biomed Announces Pricing of $3.0 Million Follow-On Offering of Ordinary Shares and Warrants

www.stocktitan.net/news/MYNZ/mainz-biomed-a...

StockTitan

@stocktitan.net

8 months ago

Mainz Biomed and CARE Conclude Cooperation Agreement for Joint Care Concept for Health Insurance Companies Mainz Biomed (NASDAQ:MYNZ) has announced a strategic collaboration with CARE diagnostica Laborreagenzien GmbH to expand colorectal cancer screening services in Germany. The partnership will integrate Mainz Biomed's ColoAlert® test into CARE's existing screening programs, which currently serve more than 15 statutory health insurance companies.The collaboration enables CARE to enhance its screening offerings by incorporating ColoAlert®'s molecular genetic analysis capabilities, which use PCR to analyze biomarkers in stool samples. This advanced technology aims to improve early-stage detection rates compared to traditional fecal immunochemical tests (FIT).

#MYNZ Mainz Biomed and CARE Conclude Cooperation Agreement for Joint Care Concept for Health Insurance Companies

www.stocktitan.net/news/MYNZ/mainz-biomed-a...

StockTitan

@stocktitan.net

8 months ago

Mainz Biomed Half Year 2025 Update: Accelerating FDA Pathway for NextGen Colorectal Cancer Screening and Expansion with Pancreatic Cancer Screening Acquisition Mainz Biomed (NASDAQ:MYNZ) reported significant progress in H1 2025, focusing on advancing its colorectal and pancreatic cancer screening technologies. The company launched eAArly DETECT 2, a US feasibility study evaluating its next-gen colorectal cancer test across 2,000 average-risk patients.A key development was the License and Option Agreement with Liquid Biosciences for pancreatic cancer screening biomarkers, which demonstrated 95% sensitivity and 98% specificity in initial studies. The company secured public funding from ISB for up to 50% of the pancreatic cancer project costs.Additionally, Mainz Biomed expanded its market presence through partnerships with labor team w ag in Switzerland and EDX Medical Group in the UK. The company also completed a $4.0 million follow-on offering and regained full Nasdaq compliance.

#MYNZ Mainz Biomed Half Year 2025 Update: Accelerating FDA Pathway for NextGen Colorectal Cancer Screening and Expansion with Pancreatic Cancer Screening Acquisition

www.stocktitan.net/news/MYNZ/mainz-biomed-h...

StockTitan

@stocktitan.net

9 months ago

Mainz Biomed Secures Public Funding to Advance Innovative Pancreatic Cancer Screening Test Mainz Biomed (NASDAQ:MYNZ) has secured significant public funding from the Investitions- und Strukturbank Rheinland-Pfalz (ISB) for its pancreatic cancer screening test development. The ISB will fund up to 50% of the total project costs through its Innovation and Technology Support Program.The company is currently in the feasibility phase, collaborating with Crown Bioscience to evaluate a panel of mRNA biomarkers and a machine learning-driven algorithm using clinical blood samples. This non-invasive, blood-based screening test aims to enable earlier detection of pancreatic cancer, potentially improving treatment outcomes.

#MYNZ Mainz Biomed Secures Public Funding to Advance Innovative Pancreatic Cancer Screening Test

www.stocktitan.net/news/MYNZ/mainz-biomed-s...

Market Wire News

@marketwirenews.com

9 months ago

News; ( NASDAQ: #MYNZ ) Where are the Opportunities in (MYNZ)

PRISM MarketView

@prismmarketview.bsky.social

9 months ago

Mainz Biomed Advances Blood-Based Pancreatic Cancer Test with New Feasibility Study Mainz Biomed (NASDAQ: MYNZ) announced the launch of a feasibility study for PancAlert, its blood-based screening test for early detection of pancreatic cancer.

#MainzBioMed #MYNZ announced the launch of a feasibility study for PancAlert, its blood-based screening test for early detection of pancreatic cancer.

prismmarketview.com/mainz-biomed...

StockTitan

@stocktitan.net

9 months ago

Revolutionary Blood Test Detects Pancreatic Cancer with 95% Accuracy, Mainz Biomed Study Reveals New blood-based screening achieves 98% specificity in early pancreatic cancer detection. Mainz advances to feasibility phase with Crown Bioscience partnership. Learn more.

#MYNZ Mainz Biomed Initiates Feasibility Study of Biomarker Panel in Pancreatic Cancer Project

www.stocktitan.net/news/MYNZ/mainz-biomed-i...

StockTitan

@stocktitan.net

10 months ago

Mainz Biomed Announces Pricing of $4.0 Million Follow-On Offering of Ordinary Shares and Warrants Mainz Biomed (NASDAQ:MYNZ) has announced the pricing of a $4.0 million follow-on offering, consisting of 2,000,000 units priced at $2.00 per unit. Each unit includes one ordinary share (or pre-funded warrant), one Series A warrant, and one Series B warrant to purchase ordinary shares. The Series A warrants have a 5-year term, while Series B warrants expire either 30 days after eAArly Detect 2 study results or one year from issuance. Both warrant series are immediately exercisable at $2.00 per share. Additionally, the company has amended previous December 2024 warrants, reducing their exercise price to $2.00 for both Series A (1,367,521 shares) and Series B (1,367,521 shares). Maxim Group LLC is serving as the sole placement agent, with the offering expected to close around May 21, 2025.

#MYNZ Mainz Biomed Announces Pricing of $4.0 Million Follow-On Offering of Ordinary Shares and Warrants

www.stocktitan.net/news/MYNZ/mainz-biomed-a...

StockTitan

@stocktitan.net

10 months ago

Mainz Biomed Announces Interim Read Out For Its eAArly DETECT 2 Clinical Study Mainz Biomed (NASDAQ:MYNZ) announced plans to provide an interim read out of its eAArly DETECT 2 feasibility study by the end of summer 2025, with top-line results expected in Q4 2025. The study evaluates the company's next-generation colorectal cancer (CRC) screening test across approximately 2,000 average-risk patients.The test combines proprietary mRNA biomarkers, an AI-developed algorithm, and a FIT test to detect both cancerous polyps and precancerous adenomas. Based on the study's outcome, Mainz Biomed plans to finalize protocols for ReconAAsense, its U.S. pivotal study, scheduled to begin in 2026.The company's five novel gene expression biomarkers, acquired from Sherbrooke University in 2022, have shown capability in identifying advanced adenomas and early-stage CRC, potentially advancing CRC screening to prevention.

#MYNZ Mainz Biomed Announces Interim Read Out For Its eAArly DETECT 2 Clinical Study

www.stocktitan.net/news/MYNZ/mainz-biomed-a...

StockTitan

@stocktitan.net

11 months ago

Mainz Biomed Enters into Technology Partnership with EDX Medical Group Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, has entered into a technology partnership with UK-based EDX Medical

#MYNZ Mainz Biomed Enters into Technology Partnership with EDX Medical Group

www.stocktitan.net/news/MYNZ/mainz-biomed-e...

StockTitan

@stocktitan.net

11 months ago

Mainz Biomed's Game-Changing Cancer Test Shows 98% Accuracy as Company Expands European Presence New cancer screening breakthrough achieves 95% sensitivity in latest trials. Mainz expands into Switzerland while advancing next-gen CRC detection platform. See full results.

#MYNZ Mainz Biomed Provides First Quarter 2025 Corporate Update and Path to FDA Premarket Approval

www.stocktitan.net/news/MYNZ/mainz-biomed-p...

StockTitan

@stocktitan.net

1 year ago

Mainz Biomed Achieves Double-Digit Growth: Key Partnerships Fuel Expansion in Cancer Screening Latest earnings reveal 33% lab revenue surge for ColoAlert® in Europe, backed by Thermo Fisher and Quest partnerships. See full financial analysis and growth strategy.

#MYNZ Mainz Biomed Reports 2024 Financial Results and Provides Corporate Update

www.stocktitan.net/news/MYNZ/mainz-biomed-r...

StockTitan

@stocktitan.net

1 year ago

Revolutionary AI-Powered Cancer Test: Mainz Biomed Begins Major Clinical Trial Novel mRNA and AI-powered technology aims to transform early colorectal cancer detection. 2,000-patient study evaluates breakthrough screening approach. Full analysis inside.

#MYNZ Mainz Biomed Enrolls First Patient in Its eAArly DETECT 2 Clinical Study

www.stocktitan.net/news/MYNZ/mainz-biomed-e...

StockTitan

@stocktitan.net

1 year ago

Revolutionary mRNA Blood Test Detects Pancreatic Cancer with Near-Perfect Accuracy Mainz Biomed secures exclusive rights to groundbreaking mRNA biomarkers enabling blood-based pancreatic cancer screening with 95% sensitivity. Partnership targets FDA approval.

#MYNZ Mainz Biomed and Liquid Biosciences Make Groundbreaking Discovery of mRNA Biomarkers for Blood Based Detection of Pancreatic Cancer

www.stocktitan.net/news/MYNZ/mainz-biomed-a...

StockTitan

@stocktitan.net

1 year ago

First DNA-Based Cancer Test Enters Swiss Market: Can Mainz Biomed Transform Screening? Strategic partnership with labor team w brings ColoAlert® to Switzerland, marking first DNA-based colorectal cancer screening entry in Swiss healthcare market

#MYNZ Mainz Biomed Expands into Switzerland with labor team w

www.stocktitan.net/news/MYNZ/mainz-biomed-e...

StockTitan

@stocktitan.net

1 year ago

Mainz Biomed Launches Major U.S. Study for AI-Powered Colorectal Cancer Detection Test Mainz Biomed initiates eAArly DETECT 2 study with 2,000 patients, evaluating novel mRNA biomarkers and AI algorithm for advanced colorectal cancer screening technology.

#MYNZ Mainz Biomed Initiates U.S. Clinical Study to Evaluate Performance of Next Generation Test on Advanced Adenomas over Large Patient Population

www.stocktitan.net/news/MYNZ/mainz-biomed-i...

Market Wire News

@marketwirenews.com

1 year ago

BREAKING NEWS: ( NASDAQ: #MYNZ ) Mainz Biomed Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening Test

#StockMarket #News